This claim was a concern because it suggested that we would not have what is called freedom to operate in terms of using our drug to treat constipation and IBS-C.In September, we announced that we had come to an agreement with Ironwood in which Synergy now has clarity -- in terms of our investors', freedom -- to operate in terms of our commercialization of Plecanatide or potential commercialization